Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
Il Minn, David J Huss, Hye-Hyun Ahn, Tamara M Chinn, Andrew Park, Jon Jones, Mary Brummet, Steven P Rowe, Polina Sysa-Shah, Yong Du, Hyam I Levitsky, Martin G Pomper, Il Minn, David J Huss, Hye-Hyun Ahn, Tamara M Chinn, Andrew Park, Jon Jones, Mary Brummet, Steven P Rowe, Polina Sysa-Shah, Yong Du, Hyam I Levitsky, Martin G Pomper
Abstract
Chimeric antigen receptor (CAR) T cell therapy for hematologic malignancies is fraught with several unknowns, including number of functional T cells that engage target tumor, durability and subsequent expansion and contraction of that engagement, and whether toxicity can be managed. Non-invasive, serial imaging of CAR T cell therapy using a reporter transgene can address those issues quantitatively. We have transduced anti-CD19 CAR T cells with the prostate-specific membrane antigen (PSMA) because it is a human protein with restricted normal tissue expression and has an expanding array of positron emission tomography (PET) and therapeutic radioligands. We demonstrate that CD19-tPSMA(N9del) CAR T cells can be tracked with [18F]DCFPyL PET in a Nalm6 model of acute lymphoblastic leukemia. Divergence between the number of CD19-tPSMA(N9del) CAR T cells in peripheral blood and bone marrow and those in tumor was evident. These findings underscore the need for non-invasive repeatable monitoring of CAR T cell disposition clinically.
Figures
References
- Kochenderfer J. N., Wilson W. H., Janik J. E., Dudley M. E., Stetler-Stevenson M., Feldman S. A., Maric I., Raffeld M., Nathan D.-A., Lanier B. J., Morgan R. A., Rosenberg S. A., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010).
- Porter D. L., Levine B. L., Kalos M., Bagg A., June C. H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
- Brentjens R. J., Davila M. L., Riviere I., Park J., Wang X., Cowell L. G., Bartido S., Stefanski J., Taylor C., Olszewska M., Borquez-Ojeda O., Qu J., Wasielewska T., He Q., Bernal Y., Rijo I. V., Hedvat C., Kobos R., Curran K., Steinherz P., Jurcic J., Rosenblat T., Maslak P., Frattini M., Sadelain M., CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
- Grupp S. A., Kalos M., Barrett D., Aplenc R., Porter D. L., Rheingold S. R., Teachey D. T., Chew A., Hauck B., Wright J. F., Milone M. C., Levine B. L., June C. H., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
- Milone M. C., Bhoj V. G., The Pharmacology of T cell therapies. Mol. Ther. Methods Clin. Dev. 8, 210–221 (2018).
- Srivastava S., Riddell S. R., Engineering CAR-T cells: Design concepts. Trends Immunol. 36, 494–502 (2015).
- Ali S. A., Shi V., Maric I., Wang M., Stroncek D. F., Rose J. J., Brudno J. N., Stetler-Stevenson M., Feldman S. A., Hansen B. G., Fellowes V. S., Hakim F. T., Gress R. E., Kochenderfer J. N., T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688–1700 (2016).
- Mueller K. T., Maude S. L., Porter D. L., Frey N., Wood P., Han X., Waldron E., Chakraborty A., Awasthi R., Levine B. L., Melenhorst J. J., Grupp S. A., June C. H., Lacey S. F., Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 130, 2317–2325 (2017).
- Kochenderfer J. N., Somerville R. P. T., Lu T., Yang J. C., Sherry R. M., Feldman S. A., McIntyre L., Bot A., Rossi J., Lam N., Rosenberg S. A., Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol. Ther. 25, 2245–2253 (2017).
- Hay K. A., Hanafi L.-A., Li D., Gust J., Liles W. C., Wurfel M. M., López J. A., Chen J., Chung D., Harju-Baker S., Cherian S., Chen X., Riddell S. R., Maloney D. G., Turtle C. J., Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood 130, 2295–2306 (2017).
- Gust J., Hay K. A., Hanafi L. A., Li D., Myerson D., Gonzalez-Cuyar L. F., Yeung C., Liles W. C., Wurfel M., Lopez J. A., Chen J., Chung D., Harju-Baker S., Ozpolat T., Fink K. R., Riddell S. R., Maloney D. G., Turtle C. J., Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404–1419 (2017).
- Emami-Shahri N., Papa S., Dynamic imaging for CAR-T-cell therapy. Biochem. Soc. Trans. 44, 386–390 (2016).
- Chapelin F., Gao S., Okada H., Weber T. G., Messer K., Ahrens E. T., Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model. Sci. Rep. 7, 17748 (2017).
- Emami-Shahri N., Foster J., Kashani R., Gazinska P., Cook C., Sosabowski J., Maher J., Papa S., Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells. Nat. Commun. 9, 1081 (2018).
- Keu K. V., Witney T. H., Yaghoubi S. S., Rosenberg J., Kurien A., Magnusson R., Williams J., Habte F., Wagner J. R., Forman S., Brown C., Allen-Auerbach M., Czernin J., Tang W., Jensen M. D., Badie B., Gambhir S. S., Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci. Transl. Med. 9, eaag2196 (2017).
- Vedyvas Y., Shevlin E., Zaman M., Min I. M., Amor-Coarasa A., Park S., Park S., Kwon K.-W., Smith T., Luo Y., Kim D., Kim Y., Law B., Ting R., Babich J., Jin M. M., Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight 1, e90064 (2016).
- Wei W., Jiang D., Ehlerding E. B., Luo Q., Cai W., Noninvasive PET Imaging of T cells. Trends Cancer 4, 359–373 (2018).
- Zhang Y., Bressler J. P., Neal J., Lal B., Bhang H.-E., Laterra J., Pomper M. G., ABCG2/BCRP expression modulates D-Luciferin–based bioluminescence imaging. Cancer Res. 67, 9389–9397 (2007).
- Lee S. B., Lee H. W., Lee H. J., Jeon Y. H., Lee S.-W., Ahn B.-C., Jeong S. Y., Tracking dendritic cell migration into lymph nodes by using a novel PET probe 18F-tetrafluoroborate for sodium/iodide symporter. EJNMMI Res. 7, 32 (2017).
- Bhanat E., Koch C. A., Parmar R., Garia V., Vijayakumar V., Somatostatin receptor expression in non-classical locations—Clinical relevance? Rev. Endocr. Metab. Disord. 19, 123–132 (2018).
- Castanares M. A., Mukherjee A., Chowdhury W. H., Liu M., Chen Y., Mease R. C., Wang Y., Rodriguez R., Lupold S. E., Pomper M. G., Evaluation of prostate-specific membrane antigen as an imaging reporter. J. Nucl. Med. 55, 805–811 (2014).
- Sweat S. D., Pacelli A., Murphy G. P., Bostwick D. G., Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52, 637–640 (1998).
- Silver D. A., Pellicer I., Fair W. R., Heston W. D., Cordon-Cardo C., Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81–85 (1997).
- Szabo Z., Mena E., Rowe S. P., Plyku D., Nidal R., Eisenberger M. A., Antonarakis E. S., Fan H., Dannals R. F., Chen Y., Mease R. C., Vranesic M., Bhatnagar A., Sgouros G., Cho S. Y., Pomper M. G., Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol. Imaging Biol. 17, 565–574 (2015).
- Rowe S. P., Macura K. J., Mena E., Blackford A. L., Nadal R., Antonarakis E. S., Eisenberger M., Carducci M., Fan H., Dannals R. F., Chen Y., Mease R. C., Szabo Z., Pomper M. G., Cho S. Y., PSMA-based [18F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol. Imaging Biol. 18, 411–419 (2016).
- Werner R. A., Bundschuh R. A., Budndschuh L., Javadi M. S., Leal J. P., Higuchi T., Pienta K. J., Buck A. K., Pomper M. G., Gorin M. A., Lapa C., Rowe S. P., Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging. J. Nucl. Med. 59, 1857–1864 (2018).
- Rowe S. P., Pienta K. J., Pomper M. G., Gorin M. A., PSMA-RADS version 1.0: A step towards standardizing the interpretation and reporting of PSMA–targeted PET imaging studies. Eur. Urol. 73, 485–487 (2018).
- Rowe S. P., Pienta K. J., Pomper M. G., Gorin M. A., Proposal for a structured reporting system for prostate-specific membrane antigen–targeted PET imaging: PSMA-RADS version 1.0. J. Nucl. Med. 59, 479–485 (2018).
- Ravert H. T., Holt D. P., Chen Y., Mease R. C., Fan H., Pomper M. G., Dannals R. F., An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL. J. Labelled Comp. Radiopharm. 59, 439–450 (2016).
- Rajasekaran S. A., Anilkumar G., Oshima E., Bowie J. U., Liu H., Heston W., Bander N. H., Rajasekaran A. K., A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell 14, 4835–4845 (2003).
- Turtle C. J., Hanafi L.-A., Berger C., Gooley T. A., Cherian S., Hudecek M., Sommermeyer D., Melville K., Pender B., Budiarto T. M., Robinson E., Steevens N. N., Chaney C., Soma L., Chen X., Yeung C., Wood B., Li D., Cao J., Heimfeld S., Jensen M. C., Riddell S. R., Maloney D. G., CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).
- Zhao Z., Condomines M., van der Stegen S. J. C., Perna F., Kloss C. C., Gunset G., Plotkin J., Sadelain M., Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415–428 (2015).
- Chen Y., Pullambhatla M., Byun Y., Foss C. A., Nimmagadda S., Senthamizhchelvan S., Sgouros G., Mease R. C., Pomper M. G., 2-(3-{1carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 17, 7645–7653 (2011).
- Dietlein M., Kobe C., Kuhnert G., Stockter S., Fischer T., Schomacker K., Schmidt M., Dietlein F., Zlatopolskiy B. D., Krapf P., Richarz R., Neubauer S., Drzezga A., Neumaier B., Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol. Imaging Biol. 17, 575–584 (2015).
- Robu S., Schmidt A., Eiber M., Schottelius M., Günther T., Hooshyar Yousefi B., Schwaiger M., Wester H.-J., Synthesis and preclinical evaluation of novel 18F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: A comparison with 18F-DCFPyl and 18F-PSMA-1007. EJNMMI Res. 8, 30 (2018).
- Bouchkouj N., Kasamon Y. L., de Claro R. A., George B., Lin X., Lee S., Blumenthal G. M., Bryan W., McKee A. E., Pazdur R., FDA approval summary: Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Clin. Cancer Res. 25, 1702–1708 (2018).
- Morgan M. A., Schambach A., Engineering CAR-T cells for improved function against solid tumors. Front. Immunol. 9, 2493 (2018).
- Calais J., Fendler W. P., Eiber M., Gartmann J., Chu F. I., Nickols N. G., Reiter R. E., Rettig M. B., Marks L. S., Ahlering T. E., Huynh L. M., Slavik R., Gupta P., Quon A., Allen-Auerbach M. S., Czernin J., Herrmann K., Impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence. J. Nucl. Med. 59, 434–441 (2018).
- Emmett L., Crumbaker M., Ho B., Willowson K., Eu P., Ratnayake L., Epstein R., Blanksby A., Horvath L., Guminski A., Mahon K., Gedye C., Yin C., Stricker P., Joshua A. M., Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin. Genitourin. Cancer (2018).
- Gust J., Taraseviciute A., Turtle C. J., Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32, 1091–1101 (2018).
Source: PubMed